Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T39372 |
CDK7-IN-1
CDK7-IN-1 |
||
CDK7-IN-1 is an analog derived from YKL-5-124 and functions as an inhibitor of cyclin-dependent kinase 7 (cdk7). It exhibits strong inhibitory activity, with an IC50 value of less than 100 nM (WO 2016105528 A2, Compound 215). | |||
T7296 |
THZ2
CDK7-IN-1 |
CDK | Cell Cycle/Checkpoint |
THZ2 (CDK7-IN-1) 是 THZ1 的类似物,是一种有效的选择性 CDK7 抑制剂 ,IC50值为 13.9 nM。它有治疗三阴性乳腺癌的潜力。 | |||
T40353 |
CDK7/9-IN-1
CDK7/9-IN-1 |
||
CDK7/9-IN-1 is a specific inhibitor of cyclin-dependent kinases 7/9 (CDK7/9). It specifically targets CDK7, while also displaying inhibitory activity against CDK9. CDK7/9-IN-1 demonstrates excellent inhibitory potency against CDK7, with IC50 values of 0.0656 μM and 0.00574 μM without pre-incubation and after 3 hours pre-incubation, respectively. Furthermore, CDK7/9-IN-1 inhibits CDK9 with an IC50 of 2.14 μM after 3 hours pre-incubation. Its application in cancer research makes it valuable for su... | |||
T82227 |
HDAC1/CDK7-IN-1
|
HDAC | Chromatin/Epigenetic; DNA Damage/DNA Repair |
HDAC1/CDK7-IN-1(compound 8e)是一款针对CDK7和HDAC1的双重抑制剂,其IC50值分别为893 nM 和248 nM 。该化合物能有效抑制MDA-MB-231、MCF-7、A549及HCT-116等多种癌细胞系的生长。此外,HDAC1/CDK7-IN-1在HCT-116细胞中诱发了细胞周期阻滞与凋亡(apoptosis)现象,并能够抑制其细胞迁移能力。 | |||
T62926 |
CDK7/12-IN-1
|
||
CDK7/12-IN-1 是一种 CDK7/12 的选择性抑制剂,作用于 CDK7 (IC50: 3 nM) 和 CDK 12 (IC50: 277 nM)。抑制 CDK7 和 CDK12 是一种有效抑制肿瘤生长的有效。 | |||
T79169 | CDK7-IN-22 | CDK | Cell Cycle/Checkpoint |
CDK7-IN-22 (compound 101)为CDK7选择性抑制剂,具备抗肿瘤活性。 | |||
T75121 | CDK7-IN-21 | ||
CDK7-IN-21 (compound A22) 是一种有效的 CDK7抑制剂。 | |||
T62791 | CDK7-IN-16 | ||
CDK7-IN-16 (compound 9) 是一种 CDK 7 的有效抑制剂 (IC50: 1-10 nM)。CDK7-IN-16 能够用于研究抗癌,特别是转录异常的癌症。 | |||
T79881 |
CDK7-IN-25
|
CDK | Cell Cycle/Checkpoint |
CDK7-IN-25 (CY-16-1)为一CDK-7抑制剂,具有极低的半抑制浓度(IC50<1nM),主要用于癌症研究领域。 | |||
T36743 |
CDK7/9 tide
|
||
CDK7/9 tide is peptide substrate for CDK7 or CDK9[1]. [1]. Robert T, et, al. Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors. Front Chem. 2020 Feb 27; 8:147. | |||
T14915 |
CDK12-IN-E9
|
CDK | Cell Cycle/Checkpoint |
CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and non-covalent CDK9 inhibitor while avoiding ABC transporter-mediated efflux. It has a weak binding ability to CDK7/CyclinH complex (IC50> 1 μM). | |||
T79604 |
SHR5428
|
CDK | Cell Cycle/Checkpoint |
SHR5428为口服选择性非共价CDK7抑制剂,显示出高效CDK7酶活性抑制(IC50=2.3 nM)。它还有效抑制MDA-MB-468细胞系中的三阴性乳腺癌细胞活性(IC50=6.6 nM)。 | |||
T70988 |
Ibulocydine
|
||
Ibulocydine is a potent CDK inhibitor. Ibulocydine has high activity against Cdk7/cyclin H/Mat1 and Cdk9/cyclin T. Ibulocydine inhibited the growth of HCC cells more effectively than other Cdk inhibitors, including olomoucine and roscovitine, whereas ibulocydine as well as the other Cdk inhibitors and BMK-Y101 minimally influenced the growth of normal hepatocyte cells. Ibulocydine induced apoptosis in HCC cells, most likely by inhibiting Cdk7 and Cdk9. In vitro treatment of HCC cells with ibuloc... |